Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions
Pouchitis
Interventions
BIOLOGICAL

Active FMT, then open label FMT

Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.

BIOLOGICAL

Placebo FMT, then open label FMT

Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.

Trial Locations (1)

27599

University of North Carolina, Chapel Hill

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OpenBiome

INDUSTRY

collaborator

Crohn's and Colitis Foundation

OTHER

collaborator

The Broad Foundation

OTHER

lead

University of North Carolina, Chapel Hill

OTHER